Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 7/20 | 0.59 |
| ▸ | TACR2 | P21452 | 6/20 | 0.59 |
| ▸ | TRPV4 | Q9HBA0 | 15/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6394399 | 0.91 | TACR2 (0.57) | TACR3TACR2TRPV4OPRM1KCNH2 | |
| Hydrochloric Acid SCHEMBL6399854 | 0.91 | TACR2 (0.57) | TACR3TACR2TRPV4OPRM1KCNH2 | |
| SCHEMBL5203642 | 0.87 | TRPV4 (0.73) | TACR3TACR2TRPV4OPRM1KCNH2 | |
| SCHEMBL5203685 | 0.86 | TACR2 (0.57) | TACR3TACR2TRPV4OPRM1KCNH2 | |
| SCHEMBL6528864 | 0.82 | TRPV4 (0.55) | TACR3TACR2TRPV4OPRM1KCNH2 | |
| SCHEMBL6393346 | 0.81 | TRPV4 (0.58) | TACR3TACR2TRPV4OPRM1KCNH2 | |
| SCHEMBL6598792 | 0.81 | TACR2 (0.49) | TACR3TACR2TRPV4OPRM1 | |
| SCHEMBL6506812 | 0.79 | TRPV4 (0.58) | TACR3TACR2TRPV4OPRM1KCNH2 | |
| SCHEMBL5202872 | 0.79 | HPGD (0.52) | — | |
| SCHEMBL5945437 | 0.79 | TRPV4 (0.65) | TACR3TACR2TRPV4OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377555-B1 | A DIOXINO[2,3-G]QUINOLINE-9-CARBOXYLIC ACID DERIVATIVE AS NK3 RECEPTOR ANTAGONIST | GLAXOSMITHKLINE SPA (IT) | 2007-01-24 | — | — | EP | disclosed |
| US-20050182093-A1 | Novel compounds | GLAXOSMITHKLINE S.P.A. | 2005-08-18 | — | — | US | disclosed |
| US-20040152730-A1 | Novel compounds | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-05 | — | — | US | disclosed |
| EP-1377555-A1 | NOVEL COMPOUNDS | GlaxoSmithKline S.p.A. (IT) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002083645-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE S.P.A. (IT) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182093-A1 | Novel compounds | SLC10A1, AVPR2, REN | TACR3 3323/4885TACR2 1103/4885TRPV4 1507/4885 |
| US-20040152730-A1 | Novel compounds | SLC10A1, AVPR2, REN | TACR3 3323/4885TACR2 1103/4885TRPV4 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.